NasdaqCM - Nasdaq Real Time Price
USD
Cyclerion Therapeutics, Inc. (CYCN)
6.38
+4.83
(+311.61%)
At close: April 1 at 4:00:03 PM EDT
5.93
-0.45
(-7.05%)
Overnight: 2:20:28 AM EDT
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed.
Loading chart for CYCN
Chart does not reflect overnight price.
- Previous Close
1.55 - Open
5.43 - Bid 5.07 x 200
- Ask 7.24 x 200
- Day's Range
5.39 - 8.48 - 52 Week Range
1.03 - 8.48 - Volume
252,321,938 - Avg. Volume
5,808,103 - Market Cap (intraday)
24.284M - Beta (5Y Monthly) 1.02
- PE Ratio (TTM)
-- - EPS (TTM)
-1.11 - Earnings Date (est.) --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.00
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
www.cyclerion.comRecent News: CYCN
View More
Performance Overview: CYCN
Trailing total returns as of 4/1/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
CYCN
402.36%
S&P 500 (^GSPC)
3.95%
1-Year Return
CYCN
151.18%
S&P 500 (^GSPC)
16.73%
3-Year Return
CYCN
26.50%
S&P 500 (^GSPC)
60.01%
5-Year Return
CYCN
90.30%
S&P 500 (^GSPC)
63.57%
Earnings Trends: CYCN
View MoreAnalyst Insights: CYCN
View MoreStatistics: CYCN
View MoreValuation Measures
As of 3/31/2026
-
Market Cap
5.90M
-
Enterprise Value
1.33M
-
Trailing P/E
--
-
Forward P/E
--
-
PEG Ratio (5yr expected)
--
-
Price/Sales (ttm)
1.55
-
Price/Book (mrq)
0.62
-
Enterprise Value/Revenue
0.47
-
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
-
Profit Margin
-77.02%
-
Return on Assets (ttm)
-23.51%
-
Return on Equity (ttm)
-24.80%
-
Revenue (ttm)
2.85M
-
Net Income Avi to Common (ttm)
-2.2M
-
Diluted EPS (ttm)
-1.11
Balance Sheet and Cash Flow
-
Total Cash (mrq)
4.57M
-
Total Debt/Equity (mrq)
--
-
Levered Free Cash Flow (ttm)
-1.45M
Compare To: CYCN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights: CYCN
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
